221 CRESCENT STREET, WALTHAM, MA
Investor Presentation
Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Viridian Therapeutics Enters Underwriting Agreement for $251.35M Offering
Company Expects Approximately $490.9 Million in Cash as of September 30, 2025
Viridian Therapeutics Enters $300 Million Purchase and Sale Agreement
Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
Viridian Therapeutics Partners with Kissei for Veligrotug and VRDN-003 in Japan, $70M Upfront, $315M Milestones
FY 2024
Q3
Q2
Q1
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Statement of Changes in Beneficial Ownership
S-8 POS
Correspondence
Submission Upload